Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
362 Leser
Artikel bewerten:
(1)

Pharnext 2019 Universal Registration Document Approved by AMF

DJ Pharnext 2019 Universal Registration Document Approved by AMF

Pharnext 
Pharnext 2019 Universal Registration Document Approved by AMF 
 
10-Nov-2020 / 08:30 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
*PARIS, France, 08:30 a.m. CET, November 10, 2020 - Pharnext SA (FR0011191287 - 
ALPHA)*, an advanced late-stage clinical biopharmaceutical company pioneering new 
approaches to developing innovative drug combinations based on big genomics data and 
artificial intelligence ("Company") using its PLEOTHERAPY platform, today announced 
that its 2019 Universal Registration Document has been approved by the _Autorité des 
Marchés Financiers_ (AMF) on November 9, 2020 under number N° R. 20-029. 
 
The Universal Registration Document is available to the public, in English only, on 
Pharnext website at www.pharnext.com [1], under Investors/Regulated Information and 
also on the AMF website at www.amf-france.org [2]. Copies of this Universal 
Registration Document are available free of charge from Pharnext (46, rue Saint-Lazare 
75009 Paris). 
 
*About Pharnext* 
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel 
therapeutics for orphan and common neurodegenerative diseases that currently lack 
curative and/or disease-modifying treatments. Pharnext has two lead products in 
clinical development. PXT3003 completed an international Phase III trial with positive 
topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits 
from orphan drug status in Europe and the United States. PXT864 has generated 
encouraging Phase II results in Alzheimer's disease and will be advanced through 
partnerships. Pharnext has developed a new drug discovery paradigm based on big 
genomics data and artificial intelligence: PLEOTHERAPY. Pharnext identifies and 
develops synergic combinations of drugs called PLEODRUG. The Company was founded by 
renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in 
modern genomics, and is supported by a world-class scientific team. More information 
can be found at www.pharnext.com [1]. 
 
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: 
FR0011191287). 
 
*Disclaimer* 
This press release contains certain forward-looking statements concerning Pharnext and 
its business, including in respect of timing of and prospects for clinical trials and 
regulatory submissions of the Company's product candidates as well as a potential 
financing transaction, the use of proceeds therefrom and cash runway. Such 
forward-looking statements are based on assumptions that Pharnext considers to be 
reasonable. However, there can be no assurance that the estimates contained in such 
forward-looking statements will be verified, which estimates are subject to numerous 
risks including the risks set forth in Pharnext's URD approved by the AMF on November 
9, 2020 under number N° R. 20-029 as well as in its annual periodic management reports 
and press releases (copies of which are available on www.pharnext.com) and to the 
development of economic conditions, financial markets and the markets in which Pharnext 
operates. The forward-looking statements contained in this press release are also 
subject to risks not yet known to Pharnext or not currently considered material by 
Pharnext. The occurrence of all or part of such risks could cause actual results, 
financial conditions, performance or achievements of Pharnext to be materially 
different from such forward-looking statements. Pharnext disclaims any intention or 
obligation to publicly update or revise any forward-looking statements, whether as a 
result of new information, future events, or otherwise.] 
This press release and the information that it contains do not constitute an offer to 
sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, 
Pharnext shares in any country, including the United States. The Company's securities 
may not be offered or sold in the United States absent registration or an exemption 
from registration; any public offering of securities to be made in the United States 
will be made by means of a prospectus that may be obtained from the issuer that will 
contain detailed information about the Company and management, as well as financial 
statements. 
. 
 
*Contacts* 
 
David Horn Solomon 
Chief Executive Officer 
contact@pharnext.com 
+33 (0)1 41 09 22 30 
*Media Relations             *Media Relations       *Media Relations (France)* 
(International)*             (U.S.)*                Ulysse Communication 
Consilium Strategic          Rooney Partners LLC    Bruno Arabian 
Communications               Jeffrey Freedman       +33 (0)6 87 88 47 26 
Mary-Jane Elliott            jfreedman@rooneyco.com barabian 
Sukaina Virji                +1 646 432 0191        [3]@ulysse-communication.com 
Alexandra Harrison                                  Pierre-Louis Germain 
pharnext@consilium-comms.com                        +33 (0)6 64 79 97 51 
                                                    plgermain@ulysse-communication.com 
                                                    +33 (0)1 81 70 96 30 
*Investors Relations (U.S.)* *Financial 
Stern Investor Relations,    Communication 
Inc.                         **(Europe)* 
Janhavi Mohite               Actifin 
janhavi.mohite@sternir.com   Stéphane Ruiz 
+1 212 362 1200              sruiz@actifin.fr 
                             +33 (0)1 56 88 11 15 
 
Regulatory filing PDF file 
 
File: Pharnext 2019 Universal Registration Document Approved by AMF [4] 
1146775 10-Nov-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=17d7eeaeab80c33fe70ecc5ba973abc0&application_id=1146775&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ed80b2c1b904364f9fbd568bcbe0473b&application_id=1146775&site_id=vwd&application_name=news 
3: mailto:pharnext@alizerp.com 
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b58ddcafdbb3d73dd52ff5d174c3353a&application_id=1146775&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

November 10, 2020 02:30 ET (07:30 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.